Twist Bioscience (NASDAQ:TWST) Earns Buy Rating from TD Cowen

Twist Bioscience (NASDAQ:TWST)‘s stock had its “buy” rating reissued by equities researchers at TD Cowen in a report released on Tuesday,Benzinga reports. They presently have a $58.00 price objective on the stock. TD Cowen’s price target points to a potential upside of 20.03% from the company’s current price.

A number of other analysts have also recently commented on TWST. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Scotiabank boosted their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 19th. Barclays dropped their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Finally, Robert W. Baird lifted their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.00.

Twist Bioscience Stock Up 4.3 %

NASDAQ:TWST opened at $48.32 on Tuesday. The firm has a market capitalization of $2.87 billion, a P/E ratio of -13.21 and a beta of 1.78. The company has a fifty day moving average of $43.75 and a 200 day moving average of $46.20. Twist Bioscience has a 52 week low of $23.07 and a 52 week high of $60.90.

Insider Buying and Selling at Twist Bioscience

In other news, insider Dennis Cho sold 3,104 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total transaction of $134,123.84. Following the transaction, the insider now owns 75,289 shares in the company, valued at approximately $3,253,237.69. This trade represents a 3.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Paula Green sold 3,310 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $143,025.10. Following the completion of the sale, the senior vice president now owns 84,585 shares of the company’s stock, valued at approximately $3,654,917.85. This represents a 3.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,118 shares of company stock worth $4,391,151 over the last quarter. Insiders own 3.92% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Thrivent Financial for Lutherans purchased a new stake in Twist Bioscience in the third quarter valued at $43,992,000. Point72 Asset Management L.P. raised its holdings in Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after purchasing an additional 613,057 shares during the period. Fred Alger Management LLC boosted its position in Twist Bioscience by 720.7% during the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after purchasing an additional 575,080 shares in the last quarter. State Street Corp grew its holdings in Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares during the period. Finally, Wellington Management Group LLP increased its position in shares of Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after buying an additional 521,272 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.